AOM, AZN report promising Phase II data

AnorMed (TSE:AOM) and partner AstraZeneca (AZN) said data from two Phase II trials of ZD0473 platinum-based therapeutic for the second-line treatment of ovarian and small-cell lung cancers showed objective responses in both platinum therapy-sensitive and resistant patients. Data from a 29-patient study in ovarian cancer showed objective responses in 5 of 12 evaluable platinum therapy-sensitive patients and 2 of 14 evaluable platinum therapy-resistant patients. In addition, disease stabilization was observed in 3 sensitive patients and 2 resistant patients, with evidence of tumor shrinkage in 3 patients. ...